A novel assay for screening WIP1 phosphatase substrates in nuclear extracts

被引:3
|
作者
Storchova, Radka [1 ,2 ]
Burdova, Kamila [1 ]
Palek, Matous [1 ]
Medema, Rene H. [3 ]
Macurek, Libor [1 ]
机构
[1] Czech Acad Sci, Canc Cell Biol, Inst Mol Genet, Videnska 1083, Prague 14200, Czech Republic
[2] Charles Univ Prague, Fac Sci, Prague, Czech Republic
[3] Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands
关键词
acetylation; DNA damage response; p53; protein phosphatase; DNA-BINDING; ATM KINASE; P38; MAPK; P53; CHECKPOINT; ACETYLATION; PHOSPHORYLATION; PPM1D; ACTIVATION; P300;
D O I
10.1111/febs.15965
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Upon exposure to genotoxic stress, cells activate DNA damage response (DDR) that coordinates DNA repair with a temporal arrest in the cell cycle progression. DDR is triggered by activation of ataxia telangiectasia mutated/ataxia telangiectasia and Rad3-related protein kinases that phosphorylate multiple targets including tumor suppressor protein tumor suppressor p53 (p53). In addition, DNA damage can activate parallel stress response pathways [such as mitogen-activated protein kinase p38 alpha (p38)/MAPK-activated protein kinase 2 (MK2) kinases] contributing to establishing the cell cycle arrest. Wild-type p53-induced phosphatase 1 (WIP1) controls timely inactivation of DDR and is needed for recovery from the G2 checkpoint by counteracting the function of p53. Here, we developed a simple in vitro assay for testing WIP1 substrates in nuclear extracts. Whereas we did not detect any activity of WIP1 toward p38/MK2, we confirmed p53 as a substrate of WIP1. Inhibition or inactivation of WIP1 in U2OS cells increased phosphorylation of p53 at S15 and potentiated its acetylation at K382. Further, we identified Deleted in breast cancer gene 1 (DBC1) as a new substrate of WIP1 but surprisingly, depletion of DBC1 did not interfere with the ability of WIP1 to regulate p53 acetylation. Instead, we have found that WIP1 activity suppresses p53-K382 acetylation by inhibiting the interaction between p53 and the acetyltransferase p300. Newly established phosphatase assay allows an easy comparison of WIP1 ability to dephosphorylate various proteins and thus contributes to identification of its physiological substrates.
引用
收藏
页码:6035 / 6051
页数:17
相关论文
共 50 条
  • [1] Wip1 phosphatase in breast cancer
    Emelyanov, A.
    Bulavin, D. V.
    ONCOGENE, 2015, 34 (34) : 4429 - 4438
  • [2] Wip1 phosphatase in breast cancer
    A Emelyanov
    D V Bulavin
    Oncogene, 2015, 34 : 4429 - 4438
  • [4] WIP1 phosphatase at the crossroads of cancer and aging
    Le Guezennec, Xavier
    Bulavin, Dmitry V.
    TRENDS IN BIOCHEMICAL SCIENCES, 2010, 35 (02) : 109 - 114
  • [5] Phosphatase wip1 in immunity: An Overview and Update
    Shen, Xiao-Fei
    Zhao, Yang
    Jiang, Jin-Peng
    Guan, Wen-Xian
    Du, Jun-Feng
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [6] NF-kappaB is a novel transcriptional regulator of the oncogenic Wip1 phosphatase
    Lowe, Julie
    Yang, Qian
    Cha, Hyukjin
    Fornace, Albert
    CANCER RESEARCH, 2009, 69
  • [7] WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma
    Richter, Mark
    Dayaram, Tajhal
    Gilmartin, Aidan G.
    Ganji, Gopinath
    Pemmasani, Sandhya Kiran
    Van der Key, Harjeet
    Shohet, Jason M.
    Donehower, Lawrence A.
    Kumar, Rakesh
    PLOS ONE, 2015, 10 (02):
  • [8] Wip1: A candidate phosphatase for cancer diagnosis and treatment
    Bakhshaiesh, Tayebeh Oghabi
    Majidzadeh-A, Keivan
    Esmaeili, Rezvan
    DNA REPAIR, 2017, 54 : 63 - 66
  • [9] WIP1 phosphatase as pharmacological target in cancer therapy
    Pechackova, Sona
    Burdova, Kamila
    Macurek, Libor
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2017, 95 (06): : 589 - 599
  • [10] Wip1 phosphatase: a new target for anticancer therapy?
    Maprayil, Sophia
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (12) : 1354 - 1354